Jaguar Health, Inc. (JAGX)

Jaguar Health's stock has experienced significant volatility and a substantial decline over the past six months. Key events impacting the stock include a reverse stock split, Q3 2025 financials showing a slight revenue increase but a decrease in Mytesi prescription volume, clinical and regulatory milestones such as submitting an amended protocol to the FDA for its MVID clinical trial and securing a new patent for crofelemer in Short Bowel Syndrome, an FDA grant for Canalevia-CA1, and analyst sentiment with a "Strong Buy" consensus rating but a bearish trend.

Explicit information regarding the demand seasonality for Jaguar Health, Inc.'s products and services is not readily available. The company's focus on treating chronic gastrointestinal distress and rare diseases suggests that demand for its products may be less subject to seasonal fluctuations. However, there is an indication of monthly seasonality for JAGX stock performance, with March having the highest probability of a positive return and August the lowest.

Jaguar Health, Inc. is a commercial-stage pharmaceutical company focused on developing and commercializing plant-based prescription medicines for gastrointestinal distress in humans and animals. Its major products include Mytesi, an FDA-approved antidiarrheal drug for adults with HIV/AIDS, Canalevia-CA1, a conditionally approved treatment for chemotherapy-induced diarrhea in dogs, Gelclair, a non-prescription product, and Magdalena Biosciences, a joint venture focused on developing plant-derived medicines for mental health.

Jaguar Health is headquartered in San Francisco, California, and has a global presence with employees across North America, Asia, and South America. Its European subsidiary, Napo Therapeutics S.r.l., is based in Milan, Italy, and focuses on expanding crofelemer access in Europe, particularly for orphan and rare diseases.

There have been no specific events in the past year that have significantly impacted Jaguar Health, Inc.'s brand reputation, either positively or negatively, beyond the general news flow related to its clinical developments, regulatory milestones, and financial performance.

Jaguar Health is owned by a mix of institutional shareholders, insiders, and retail investors. Major shareholders include Napo Pharmaceuticals Inc., Bryan Ezralow, Zhi Yang, Bvcf Management Ltd, James J. Bochnowski, and Jonathan M. Glaser. Insider sentiment for JAGX is positive, driven by high-impact open-market purchases from insiders.